



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 MADRID

Granada, 16 November 2015

RELEVANT FACT NEURON BIO, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by companies in expansion integrated in the MAB, we hereby puts in knowledge the following information about Neuron Bio, S.A. (hereinafter “NEURON” or “Company”).

On 10 November 2015 the capital stock of the investee company Kalamata Inversiones, S.L. has been increased with €1,166,045.00 by issuing 1,166,045 new shares at a nominal amount of €1.00 each share, through a non-monetary contribution comprising the laboratory and office building located on C/Avicena, 4 of the Granada Bio Science & Technology Park (“Cube of Ideas”) and 1,005,660 shares of Neol Biosolutions, S.A. with its related liabilities.

This operation is within the restructuring process carried out by the Company in order to set up a financial structure tailored to its activity in biotechnology that is clearly separated from the real estate field. This restructuring process starts using Kalamata Inversiones, S.L. as a company related to the building matters. Kalamata Inversiones, S.L. will serve as a vehicle for the companies of the group to promote both the development of ongoing projects and the beginning of new projects, based on synergies resulting from collaborations with third parties taking as reference research activities of the sanitary biotechnology field (main activity of Neuron Bio), as well as the industrial biotechnology (main activity of Neol Biosolutions).

The company commenced the construction of the building in June 2011 and finished it in November 2013. Since the first application for electricity supply made in August 2010, the Company has unsuccessfully attempt to obtain the concession for energy supply for the building. After numerous procedures with the management of the Granada Bio Science & Technology Park, the Agency of Innovation and Development of Andalusia IDEA and the company SEVILLANA ENDESA the concession has been finally obtained in March 2015. This delay interrupted the reception process of the construction since it hindered the final testing of the facilities that finally restarted at May 2015. The reason for this delay was the lack of sufficient electric power in the Bio Science & Technology Park in which it is located. Finally, the final work certificate has



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

been obtained in September 2015 and first occupancy license has been requested. "The Cube of Ideas" is provided with the following specific facilities:

- 800 m² for animal facilities with housing capacity for 9,000 rodents and 36,000 fish including biosafety level 2 laboratories
- 200 m² for biosafety level 2 laboratories (clean rooms) for cell cultures
- 975 m² for laboratories focused on the bioindustrial activity, including an industrial pilot plant
- 400 m² for laboratories focused on the biopharmaceutical activity
- 275 m² for offices
- 130 m² for multipurpose spaces for research

The start-up of these spaces will take place during the first semester of 2016 and will allow the Company to implement the business plan related to the building. This business plan that was originally planned by the Company to begin in 2014, involves a significant invoicing increase for the provision of R&D services. Due to its ability to generate revenue through the exploitation of the facilities and animal-housing equipment, the clean-room and its related services, invoicing may well be over €3 million at maximum exploitation capacity.

Pro forma balance sheets of both companies after registering the contribution available in Spanish version.

The shares of Neol Biosolutions, S.A. have been provided at a value of €1.72 each share with reference to the listing price at the Alternative Stock Market on 30 October 2015. Considering this contribution value, valuation under heading "Investments in affiliated enterprises" includes a tacit additional added value of 6,176 thousands of Euros not reflected on the balance sheet according to prevailing accounting legislation.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors